SecBot SecBot
SECBOTREPLAY Home › Report › EW

EW · Edwards Lifesciences reported strong Q1 2026 results with sales up…

Edwards Lifesciences Corp · 8-K filed Apr 23, 2026 at 16:20 ET

At the news

BULLISHIMPACT 8/10

8-K filed Apr 23, 2026 at 16:20 ET

Edwards Lifesciences reported strong Q1 2026 results with sales up 16.7% to $1.65B and adjusted EPS of $0.78, beating consensus by $0.05. The company raised full-year 2026 guidance for sales growth to 9-11% (from 8-10%) and adjusted EPS to $2.95-$3.05 (from $2.90-$3.05), citing strong TAVR and TMTT momentum and clinical catalysts.

  • Q1 sales grew 16.7% YoY to $1.65B, constant currency growth of 12.7%
  • Q1 adjusted EPS was $0.78, beating consensus of $0.73
  • Raised full-year 2026 constant currency sales growth guidance to 9-11% (from 8-10%)
  • Raised full-year 2026 adjusted EPS guidance midpoint to $2.95-$3.05 (from $2.90-$3.05)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access